JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy

JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy

Jak inhibitors are potent anti-inflammatory drugs that have the potential to dampen the hyperactive inflammatory response associated with severe COVID-19. We reviewed the clinical outcomes of 218 patients with COVID-19 hospitalized for severe pneumonia and treated with ruxolitinib through a compassi...

Full description

Bibliographic Details
Main Authors: Alessandro Maria Vannucchi, Andrea Mortara, Andrea D’Alessio, Mara Morelli, Alberto Tedeschi, Moreno Benedetto Festuccia, Antonella D’Arminio Monforte, Enrico Capochiani, Carmine Selleri, Federico Simonetti, Annalisa Saracino, Davide Rapezzi, Maria Rita Badagliacca, Katia Falasca, Alfredo Molteni, Roberto Palazzolo, Giuliano Schettino, Monica Bocchia, Mauro Turrini, Paolo A. Ascierto, Mike Zuurman, Carole Paley, Paola Coco, Giuseppe Saglio
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Journal of Clinical Medicine
Subjects:
COVID-19
pneumonia
ruxolitinib
SARS-CoV-2
hyperactive inflammatory response
Online Access:https://www.mdpi.com/2077-0383/10/16/3752

Internet

https://www.mdpi.com/2077-0383/10/16/3752

Similar Items